Broughton R, Mamelak M
Can J Neurol Sci. 1980 Feb;7(1):23-31.
Continuous 48-hour polygraphic recordings of sleep/waking patterns were performed on 14 patients with narcolepsy-cataplexy before and after 7-10 days of treatment of their nocturnal sleep with gamma-hydroxybutyrate (GBH). GBH improved the quality of night sleep by increasing the amount of slow wave sleep, reducing stage I, increasing sleep efficiency (percentage of time in bed spent asleep), and reducing the number of periods of short sleep under 15 minutes. Also nighttime REM sleep was reduced in latency and became less fragmented. The daytime period contained less slow wave sleep and REM sleep, and fewer episodes of prolonged sleep. Patients experienced reduction or loss of daytime attacks of irresistible sleep, cataplectic attacks, and other auxiliary symptoms. Residual daytime drowsiness subsequently improved on low doses of methylphenidate. Tolerance did not develop and there were no serious toxic side-effects. Four of the patients had been refractory to previous combinations of antidepressants and high doses of stimulants.
对14例发作性睡病-猝倒症患者在使用γ-羟基丁酸（GBH）治疗夜间睡眠7 - 10天前后进行了连续48小时的睡眠/觉醒模式多导记录。GBH通过增加慢波睡眠时间、减少I期睡眠、提高睡眠效率（在床上入睡时间的百分比）以及减少短于15分钟的短睡眠期数量来改善夜间睡眠质量。夜间快速眼动（REM）睡眠的潜伏期缩短且碎片化程度降低。白天慢波睡眠和REM睡眠减少，长时间睡眠发作减少。患者白天不可抗拒的睡眠发作、猝倒发作及其他伴随症状减少或消失。随后，低剂量哌甲酯改善了残留的日间嗜睡。未出现耐受性，也没有严重的毒副作用。其中4例患者对先前的抗抑郁药和高剂量兴奋剂联合治疗无效。
